Caution: New Medicare drug plan may cause headaches

November 15, 2005

CHAMPAIGN, Ill. -- If many seniors are scratching their heads about the new Medicare prescription drug plan, so are the experts.

"A prescription for confusion" is how Richard L. Kaplan, a professor of law at the University of Illinois, characterizes the new drug benefit, whose enrollment period begins today for Americans aged 65 years and older.

Kaplan describes the plan as "fashioned like no other pharmaceutical coverage in the world."

For starters, the program, known as Medicare Part D, will be administered by private insurance companies rather than the Social Security Administration, which handles hospitalization and doctor's bills under current Medicare coverage, known as Parts A and B.

This shift means that seniors must choose between drug plans with widely differing premiums, deductibles, co-payments and covered drugs. In Kansas, for example, Medicare beneficiaries have to shop for insurance among 40 plans from insurers such as Aetna, Humana and UnitedHealth Group, which charge premiums from $9.48 a month to $67.88 a month.

The plan's configuration reflects President George W. Bush's philosophy that competition from private insurers is more efficient than a government program. It also reflects the belief that "what older Americans want is a choice of plans rather than a single plan offering a choice of providers," Kaplan said in an interview. "But the array of options is so complex that many elders will be overwhelmed, as will attorneys and others who counsel older clients."

"Some seniors will need to take a laptop computer into their medicine cabinet to accurately compare alternatives," he added. Kaplan is a vice chair of the Elder Law Committee of the American Bar Association's Senior Lawyers Division and has written frequently about Medicare in scholarly publications.

Another unusual aspect of the new plan is that, while coverage is voluntary, seniors who delay enrollment will be subject to a penalty of 1 percent per month after the close of the enrollment period on May 15, 2006.

In Kaplan's words, "A late enrollee will be accepted regardless of his or her medical condition -- unlike the medical underwriting that private insurance plans employ. But the premium that will be charged will be increased as long as the enrollee remains in Medicare Part D. Thus, a decision to defer enrollment in Part D has financial consequences if an eligible person eventually chooses to enroll in the program."

But there's an important exception: seniors who had been covered under a "creditable" drug prescription plan will not be subject to the penalty. "Creditable coverage" is defined as a drug plan that meets or exceeds the actuarial value of Medicare Part D coverage.

This could include some private-employer coverage, group health plans and veterans' drug coverage, but not most Medigap policies. (Medigap is a health insurance policy sold by private insurers to fill the "gaps" in Medicare Parts A and B).

Still another complication is the prescription drug plan's own gap in coverage, which has come to be known as the "doughnut hole."

Under the typical arrangement, the drug benefit will end once a senior reaches $2,250 in annual drug costs, and will not kick back in until drug costs exceed $5,100. The doughnut hole means that a senior who has $2,500 in drug costs will pay $1,420 out-of-pocket expenses with the drug benefit (using the government's estimated average monthly premium of $35), but will pay $3,920 -- or nearly three times more -- if drug costs reach $5,000.

"Even at a fairly catastrophic level of $10,000 per year of annual drug costs, the enrollee pays nearly 43 percent of the total bill," Kaplan noted.

Because of the doughnut hole, many retirees with existing employer-sponsored drug plans might not wish to sign up for the Medicare plan. But the caveat is that employer-sponsored drug coverage is declining rapidly -- from 80 percent of retirees covered among major U.S. companies in 1991 to 56 percent in 2003.

Last year, the federal Equal Employment Opportunity Commission approved a rule that allows employers to reduce -- or even eliminate -- company-provided health benefits to Medicare-eligible retirees. This rule reversed the agency's prior policy that such a change violates the Age Discrimination in Employment Act.

"How much more likely will employers be to terminate their plans now that Medicare Part D provides an alternative?" Kaplan asked.

The new law does provide a federal subsidy to employers who maintain their current prescription-drug coverage for retirees. "This subsidy relates to the cost of providing drug benefits only up to $5,000 per year," Kaplan wrote. "More generous prescription drug benefits yield no additional federal subsidies to the sponsoring employers. Will those employers, therefore, modify their plans to cap an individual retiree's prescription medication expenditures at $5,000 per year? No one knows, but the stakes are huge, both for employers with existing drug benefits and for their retirees."

Adding to the confusion is the problem that predicting future drug needs -- and costs -- for seniors is often impossible.

"Many potential Medicare beneficiaries may know what drugs they need now and what they cost currently, but what will those drugs cost in the future? What if a specific drug that they need is removed from their plan's formulary, with the result that the client must pay substantially more for that drug? Such a development, which is increasingly common these days, changes the entire calculus of employer-sponsored plans and managed care plans, which typically offer widely differing prices for 'included' and 'not included' pharmaceuticals."

In sum, according to Kaplan, Medicare Part D may help many seniors save on prescription drugs, especially those with incomes below 150 percent of the federal poverty line, who will receive special discounts under the new law.

But the bottom line is that seniors will still have to pay for a large portion of their drug costs after January 2006, when the program takes effect.

What's more, selecting the best coverage for an individual "will be fraught with confusion and uncertainty" as a result of the program's enormous complexity.

Kaplan's article, "The Medicare Drug Benefit: A Prescription for Confusion," is scheduled to appear later this month in the NAELA Journal published by the National Academy of Elder Law Attorneys.

University of Illinois at Urbana-Champaign

Related Medicare Articles from Brightsurf:

Falling Medicare reimbursement rates for orthopaedic trauma
The amount Medicare reimburses for orthopaedic trauma surgery has fallen by nearly one-third over the past two decades, reports a study in the Journal of Orthopaedic Trauma.

Medicare coverage varies for transgender hormone therapies
A new study has shown substantial variability in access to guideline-recommended hormone therapies for older transgender individuals insured through Medicare.

Medicare changes may increase access to TAVR
The number of hospitals providing TAVR could double with changes to Medicare requirements.

Inequitable medicare reimbursements threaten care of most vulnerable
Hospitals, doctors and Medicare Advantage insurance plans that care for some of the most vulnerable patients are not reimbursed fairly by Medicare, according to recent findings in JAMA.

Medicare may overpay for many surgical procedures
For most surgical procedures, Medicare provides physicians a single bundled payment that covers both the procedure and related postoperative care over a period of up to 90 days.

Only 1 in 4 Medicare patients participate in cardiac rehabilitation
Only about 24% of Medicare patients who could receive outpatient cardiac rehabilitation participate in the program.

How common is food insecurity among Medicare enrollees? 
Nearly 1 in 10 Medicare enrollees age 65 and over and 4 in 10 enrollees younger than 65 with long-term disabilities experience food insecurity.

Medicare for All unlikely to cause surge in hospital use: Harvard study
Despite some analysts' claims that Medicare for All would cause a sharp increase in health care utilization, a new study finds the two biggest coverage expansions in US history -- Medicare and the ACA -- caused no net increase in hospital use.

Critical heart drug too pricey for some Medicare patients
An effective drug to treat chronic heart failure may cost too much for senior citizens with a standard Medicare Part D drug plan, said a study co-authored by a John A.

Research suggests strategy for more equitable Medicare reimbursement
Those who were enrolled in both Medicare and Medicaid were sicker, had more cognitive impairments and difficulty functioning, and needed more social support than those who were not enrolled in both government programs, Saint Louis University research found.

Read More: Medicare News and Medicare Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to